Company news
Abeona Therapeutics Inc. (NASDAQ:ABEO) news
Every Abeona Therapeutics Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update
August 13, 2026
CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN®
August 4, 2026
Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®
July 21, 2026
Abeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Update
May 13, 2026
Abeona Therapeutics® Announces Activation of Children's Hospital of Philadelphia as a New Qualified Treatment Center for ZEVASKYN®
May 11, 2026
Abeona Therapeutics® Announces Date of First Quarter Financial Results
May 4, 2026
Abeona Therapeutics : reg; Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 1, 2026
Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors
April 7, 2026
Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York
April 2, 2026
Abeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates
March 17, 2026
Abeona Therapeutics® Provides Business Update Highlighting Building Momentum in ZEVASKYN® Commercial Launch
March 9, 2026
Abeona Therapeutics Announces Date of Fourth Quarter, Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Global ...
March 4, 2026
Abeona Therapeutics® Announces Date of Fourth Quarter / Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Globa...
March 3, 2026
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 31, 2025
Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer
December 15, 2025
Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas
December 11, 2025
Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy
December 8, 2025
Abeona Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates
November 13, 2025
Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates
November 12, 2025
Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation
November 7, 2025
Abeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (prademagene zamikeracel)
October 30, 2025
Abeona Therapeutics® Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs
October 20, 2025
Abeona Therapeutics® Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Selected by FDA for Rare Disease Endpoint Advanceme...
October 13, 2025
Abeona Therapeutics® and Children's Hospital Colorado Announce Newest Treatment Center for ZEVASKYN® Gene Therapy
October 8, 2025
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
August 29, 2025
Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates
August 14, 2025
AscellaHealth HUB Partnership with Abeona Therapeutics® Supports Launch Success of Novel Cell-Based Gene Therapy and Access to Treatment ...
July 29, 2025
ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area
July 15, 2025
Bio-Techne's Simple Western™ Technology Utilized in Recent FDA Approval of ZEVASKYN™ Cell-Based Gene Therapy
July 14, 2025
Abeona Therapeutics® Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million
July 2, 2025
Abeona Therapeutics® Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy
July 1, 2025
Abeona Therapeutics® added to Membership of U.S. Small-cap Russell 2000® Index and Broad-market Russell 3000® Index
June 30, 2025
Abeona Therapeutics® Announces Publication in The Lancet of Phase 3 VIITAL™ Study Data in Recessive Dystrophic Epidermolysis Bullosa
June 24, 2025
Abeona Therapeutics® to Present at the Jefferies Global Healthcare Conference
May 30, 2025
ABEO: Sells Priority Review Voucher for $155 Million…
May 19, 2025
Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates
May 15, 2025
Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder
May 14, 2025
Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder
May 14, 2025
UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder
May 14, 2025
Abeona Therapeutics® Enters into Agreement to Sell Priority Review Voucher for $155 Million
May 12, 2025
ABEO: Zevaskyn™ Approved by FDA; Raising Valuation to $11…
April 30, 2025
U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic ...
April 29, 2025
Abeona Therapeutics® Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch Plans
March 20, 2025
Abeona Therapeutics® to Present at the Leerink Partners Global Healthcare Conference
March 4, 2025
Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
November 14, 2024
Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa
November 12, 2024
Abeona Therapeutics® Announces Participation in November Investor Conferences
November 4, 2024
Abeona Therapeutics® Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration
October 29, 2024
Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors
August 14, 2024
Abeona Therapeutics® Announces Favorable Medicare Reimbursement Decisions for Pz-cel
August 13, 2024